Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. [advances In The Application Of Minimal Residual Disease In Non-metastatic Colorectal Cancer].
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. [advances In The Application Of Minimal Residual Disease In Non-metastatic Colorectal Cancer].

Related Experiment Video

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

[Advances in the application of minimal residual disease in non-metastatic colorectal cancer].

D Cao1, F Wang2, R X Zhang1

  • 1Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China.

Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
|July 15, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Minimal residual disease (MRD) detection using circulating tumor DNA (ctDNA) shows promise for predicting recurrence in non-metastatic colorectal cancer. This biomarker aids in guiding treatment decisions and monitoring patients post-surgery.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Area of Science:

  • Oncology
  • Molecular Diagnostics

Background:

  • Minimal residual disease (MRD) detection is crucial for solid tumors post-treatment.
  • MRD presence after surgery correlates with higher tumor recurrence risk.
  • Circulating tumor DNA (ctDNA) is an emerging biomarker for MRD in colorectal cancer.

Purpose of the Study:

  • To analyze the application of ctDNA for MRD detection in non-metastatic colorectal cancer (stages I-III).
  • To elaborate on ctDNA's role in guiding clinical treatment decisions.
  • To envision future directions for ctDNA detection technology in colorectal cancer.

Main Methods:

  • Review of current literature on ctDNA for MRD detection in non-metastatic colorectal cancer.
  • Analysis of ctDNA's utility in predicting recurrence and guiding adjuvant chemotherapy.
  • Exploration of ctDNA's role in post-operative monitoring.

    • Main Results:

    • ctDNA is a real-time, accurate, and convenient biomarker for MRD assessment.
    • ctDNA effectively predicts tumor recurrence in non-metastatic colorectal cancer.
    • ctDNA provides crucial information for guiding adjuvant chemotherapy and recurrence monitoring.

    Conclusions:

    • ctDNA holds significant potential for precise and individualized treatment strategies in colorectal cancer.
    • The application of ctDNA in MRD detection offers vast prospects for improving patient outcomes.
    • Further development of ctDNA detection technology is expected to enhance colorectal cancer management.